Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Soy protein and bone mineral density in older men and women: a randomized trial.
OBJECTIVE Test the hypothesis that soy isoflavone supplementation preserves bone mineral density ( BMD ) in men and women . METHODS We conducted a controlled , parallel-arm , double-blinded trial with 145 participants , 50 - 80 years , with r and om assignment to soy beverage daily for 12 months . Active treatment ( + ISO ) received soy protein containing 83 mg isoflavones ( 45.6 mg genistein , 31.7 mg daidzein ) , aglycone units ; the comparison group ( -ISO ) received soy protein containing 3 mg isoflavones . We measured BMD using dual-energy X-ray absorptiometry at the total hip and posterior-anterior spine ( L1-L4 ) at baseline in 22 women and 123 men , and at 12 months in 13 women and 98 men . We used linear mixed models to test for an isoflavone effect on percentage BMD change from baseline in spine and hip . RESULTS Among all participants , mean percent change in spine BMD ( + /-S.E. ) was 0.16+/-0.44 in -ISO ( P=0.10 ) at 12 months . Treatment effects on spine BMD were significantly greater in women than men ( P=0.01 ) . At 12 months , in women , mean percent change was 0.58+/-0.70 in + ISO and -1.84+/-0.86 in -ISO ( P=0.05 ) ; among men it was 1.32+/-0.53 in + ISO and 0.31+/-0.48 in -ISO ( P=0.16 ) . By comparison , percent change in hip BMD was similar in the treatment groups , and was not different between men and women . Mean percent change in hip BMD from baseline to 12 months was 0.54+/-0.38 in + ISO and -0.13+/-0.36 in -ISO ( P=0.20 ) among all participants . CONCLUSIONS Soy protein containing isoflavones showed a modest benefit in preserving spine , but not hip BMD in older women
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .